On March 23, a subset of "biological products" approved under the FD&C Act, such as insulin and human growth hormone (which for historical reasons were approved as drugs ) will "transition" to being regulated as biological products. Being regulated as biological products will enable transition products to serve as the reference product for biosimilar or interchangeable products approved through the abbreviated licensure pathway. Here's an FAQ about the upcoming changes.
NCPA
